new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)





Similar
Filing Names

Immunogen Inc
Immunogen Inc_20100114
  

Immunogen Inc patents

Recent patent applications related to Immunogen Inc. Immunogen Inc is listed as an Agent/Assignee. Note: Immunogen Inc may have other listings under different names/spellings. We're not affiliated with Immunogen Inc, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "I" | Immunogen Inc-related inventors




Date Immunogen Inc patents (updated weekly) - BOOKMARK this page
04/20/17 new patent  Methods of treatment using anti-erbb antibody maytansinoid conjugates
04/06/17Therapeutic combinations comprising anti-folr1 immunoconjugates
03/23/17Methods for characterizing and treating acute myeloid leukemia
03/23/17Immunoconjugates targeting cd138 and uses thereof
02/23/17Methods of preparing cytotoxic benzodiazepine derivatives
02/23/17Methods of preparing cytotoxic benzodiazepine derivatives
02/23/17Methods of preparing cytotoxic benzodiazepine derivatives
02/16/17Cytotoxic benzodiazepine derivatives
02/09/17Preparation of maytansinoid antibody conjugates by a one-step process
02/02/17Anti-cd123 antibodies and conjugates and derivatives thereof
01/19/17Conjugates of cysteine engineered antibodies
01/05/17Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
01/05/17Conjugation methods
01/05/17Compositions and methods for antibody production
12/22/16Drug conjugate composition
12/22/16Cytotoxic benzodiazepine derivatives
12/15/16Anti-cd33 antibodies and methods for treatment of acute myeloid leukemia using the same
12/08/16Ca6 antigen-specific cytotoxic conjugate and methods of using the same
11/24/16Cd37-binding molecules and immunoconjugates thereof
11/10/16Methods of preparation of conjugates
11/10/16Cd37-binding molecules and immunoconjugates thereof
09/22/16Methods for the preparation of charged crosslinkers
09/15/16Novel maytansinoid derivatives with peptide linker and conjugates thereof
08/04/16Novel benzodiazepine derivatives
05/26/16Diagnostic assays and kits for detection of folate receptor 1
05/19/16Purification of intermediates used in the preparation of heterobifunctional linkers
04/28/16Potent conjugates and hydrophilic linkers
04/28/16Cd20 antibodies and uses thereof
04/21/16Cytotoxic benzodiazepine derivatives
04/21/16Cd20 antibodies and uses thereof
04/21/16Cytotoxic benzodiazepine derivatives
04/14/16Process for manufacturing conjugates of improved homogeneity
04/07/16Conjugates comprising cell-binding agents and cytotoxic agents
04/07/16Folate receptor 1 antibodies and immunoconjugates and uses thereof
04/07/16Folate receptor 1 antibodies and immunoconjugates and uses thereof
03/24/16Cytotoxic benzodiazepine derivatives
03/24/16Folate receptor 1 antibodies and immunoconjugates and uses thereof
03/17/16Folate receptor 1 antibodies and immunoconjugates and uses thereof
03/03/16Cytotoxic agents comprising new ansamitocin derivatives
03/03/16Methods for formulating antibody drug conjugate compositions
03/03/16Folate receptor 1 antibodies and immunoconjugates and uses thereof
03/03/16Novel egfr-binding molecules and immunoconjugates thereof
02/18/16Process for preparing purified drug conjugates
02/04/16Novel maytansinoid derivatives with sulfoxide linker
01/21/16Non-antagonistic egfr-binding molecules and immunoconjugates thereof
12/17/15Conjugates comprising cell-binding agents and maytansinoids as cytotoxic agents
12/17/15Conjugates comprising cell-binding agents and cytotoxic agents
12/10/15Cross-linkers and their uses
12/03/15Anti-cd37 immunoconjugate dosing regimens
11/05/15Cytotoxic benzodiazepine derivatives
10/29/15Process for preparing stable antibody maytansinoid conjugates
10/29/15Use of an ion exchange membrane to remove impurities from cell-binding agent cytotoxic agent conjugates
10/22/15Anti-folr1 immunoconjugate dosing regimens
08/13/15Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
07/30/15Benzodiazepines and conjugates thereof
07/09/15Methods for the acylation of maytansinol
07/02/15Process for preparing purified drug conjugates
06/18/15Compounds to fibroblast growth factor receptor-3 (fgfr3) and methods of treatment
06/18/15Methods for the preparation of charged crosslinkers
05/14/15Anti-folr1 immunoconjugate dosing regimens
04/23/15Methods of treatment using anti-erbb antibody-maytansinoid conjugates
04/09/15Cytotoxic benzodiazepine derivatives
04/02/15Antibodies and assays for detection of folate receptor 1
04/02/15Methods for increasing efficacy of cd37-based therapy
03/12/15Cytotoxic agents comprising new maytansinoids (dm4)
Patent Packs
01/29/15Novel benzodiazepine derivatives
01/08/15Immunoconjugates targeting syndecan-1 expressing cells and use thereof
12/11/14Anti-folr1 immunoconjugate dosing regimens
12/11/14Methods for increasing efficacy of folr1 cancer therapy
11/27/14Use of n-hydroxysuccinimide to improve conjugate stability
09/04/14Anti-cd33 antibodies and methods for treatment of acute myeloid leukemia using the same
07/31/14Methods of treatment using anti-erbb antibody-maytansinoid conjugates
06/26/14Cross-linkers and their uses
06/26/14Conjugation methods
06/05/14Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
05/22/14Methods for the acylation of maytansinol
05/15/14Methods for the preparation of charged crosslinkers
04/10/14Novel egfr-binding molecules and immunoconjugates thereof
03/27/14Cytotoxic benzodiazepine derivatives and methods of preparation
01/23/14Non-antagonistic egfr-binding molecules and immunoconjugates thereof
Patent Packs
01/23/14Novel maytansinoid derivatives with sulfoxide linker
12/05/13Cytotoxic agents comprising new ansamitocin derivatives
11/07/13Anti-igf-i receptor antibodies, dnas, vectors, host cells and genetic constructs
06/20/13Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
05/02/13Methods of treatment using anti-erbb antibody-maytansinoid conjugates
03/28/13Anti-cd33 antibodies and methods for treatment of acute myeloid leukemia using the same
01/31/13Novel maytansinoid derivatives with peptide linker and conjugates thereof
01/10/13Cross-linkers and their uses
11/08/12Methods for increasing efficacy of folr1 cancer therapy
11/08/12Methods for decreasing ocular toxicity of antibody drug conjugates
10/25/12Compositions and methods for treatment of ovarian, peritoneal, and fallopian tube cancer
10/11/12Process for manufacturing conjugates of improved homogeneity
10/04/12Preparation of maytansinoid antibody conjugates by a one-step process
09/27/12Cytotoxic benzodiazepine derivatives
09/20/12Methods of preparation of conjugates
09/06/12Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
09/06/12Potent conjugates and hydrophilic linkers
06/28/12Methods for the preparation of charged crosslinkers
06/21/12Novel egfr-binding molecules and immunoconjugates thereof
12/29/11Elimination of heterogeneous or mixed cell population in tumors
12/08/11Drug conjugate composition
11/17/11Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates
11/17/11Prodrugs of cc-1065 analogs
08/25/11Anti-cd33 antibodies and methods for treatment of acute myeloid leukemia using the same
08/11/11Cd20 antibodies and uses thereof
08/11/11Cd20 antibodies and uses thereof
07/21/11Compositions and methods for treatment of ovarian cancer
07/07/11Process for preparing purified drug conjugates
06/30/11Cytotoxic agents comprising new maytansinoids
04/28/11Novel dosing regimen and treatment
Social Network Patent Pack
03/17/11Ca6 antigen-specific cytotoxic conjugate and methods of using the same
01/27/11Process for preparing purified drug conjugates
01/13/11Prodrugs of cc-1065 analogs
01/13/11Anti-cd33 antibodies and methods for treatment of acute myeloid leukemia using the same
01/06/11Conjugation methods
10/14/10Anti-igf-i receptor antibodies
08/12/10Novel benzodiazepine derivatives
06/03/10Methods of treatment using anti-erbb antibody-maytansinoid conjugates
05/27/10Potent conjugates and hydrophilic linkers
04/15/10Potent cell-binding agent drug conjugates
Patent Packs
02/04/10Novel synergistic effects
01/14/10Anti-igf-i receptor antibodies, dnas, vectors, host cells and genetic constructs
11/26/09Anti-cd33 antibodies and treatment of acute myeloid leukemia using the same
11/12/09Prodrugs of cc-1065 analogs
11/05/09Cross-linkers and their uses
06/25/09Anti-igf-i receptor antibody
06/18/09Anti-igf-i receptor antibody
06/04/09Drug conjugate composition
04/16/09Ca6 antigen-specific cytotoxic conjugate and methods of using the same
03/19/09Elimination of heterogeneous or mixed cell population in tumors
01/14/10Anti-igf-i receptor antibodies, dnas, vectors, host cells and genetic constructs







ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Immunogen Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immunogen Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';